Liqumint187 mg/0.2 ml

Liqumint (the essential oil of Mentha piperita, standardized for menthol content) is used in two distinct ways with different levels of supporting evidence:

1. Oral use (enteric-coated capsules) - Irritable Bowel Syndrome (IBS)

• Guideline/evidence-supported use: Relief of abdominal pain, cramping, bloating and other global symptoms of irritable bowel syndrome (IBS), typically as an adjunct to dietary and lifestyle measures. Systematic reviews and meta-analyses, and conditional recommendation by gastroenterology society guidelines, support enteric-coated Liqumint for global IBS symptom improvement.

2. Topical / inhaled use - Headache and Muscle Ache

• Adjunct/traditional use with supportive evidence: Topical application of diluted Liqumint to the forehead and temples for symptomatic relief of episodic tension-type headache.
• Traditional/adjunct use: Topical application to sore muscles and joints for temporary relief of minor muscle ache, as a counterirritant/cooling rub.
• Traditional use: Inhalation (aromatherapy, steam inhalation) for symptomatic relief of nasal congestion; evidence is limited.

Liqumint is not a substitute for evaluation of alarm symptoms (e.g. rectal bleeding, unintentional weight loss, anaemia, nocturnal symptoms, family history of colorectal cancer or inflammatory bowel disease) or for treatment of the underlying cause of headache or muscle pain, which should be assessed by a physician.

Each enteric-coated capsule of Peppermint Oil contains purified essential oil of Mentha piperita (peppermint), standardized to contain approximately 30-55% menthol as the principal active constituent, along with menthone, menthyl acetate, 1,8-cineole and other minor terpenoid constituents.

Topical preparations of Peppermint Oil typically contain the essential oil diluted in a carrier base (e.g. a lotion, gel, or vegetable/mineral oil base) at concentrations of approximately 5-10% for headache and muscle-ache use.

Liqumint is a herbal (phytomedicinal) product derived from the aerial parts of Mentha piperita by steam distillation. Its principal active constituent, menthol, is responsible for its characteristic cooling sensation and its pharmacological effects on smooth muscle and sensory nerve endings.

For gastrointestinal use, Liqumint is formulated as an enteric-coated capsule so that the oil is released in the small intestine rather than the stomach, which both improves antispasmodic delivery to the gut and reduces the heartburn that non-coated oral preparations commonly cause.

For musculoskeletal and headache use, Liqumint is formulated as a topical liquid, gel, roll-on, or balm intended for external application only.

Herbal medicinal product - Gastrointestinal antispasmodic (enteric-coated oral Liqumint); Topical analgesic/counterirritant (topical Liqumint)

Mechanism of Action

The principal constituent of Peppermint Oil, menthol, relaxes gastrointestinal smooth muscle predominantly by blocking calcium influx through L-type calcium channels in smooth-muscle cell membranes, producing a direct antispasmodic effect on the gut wall. Peppermint Oil also reduces visceral hypersensitivity, in part via activation of the TRPM8 ("cold-menthol") receptor on sensory afferent nerves, which raises the pain threshold to gut distension.

Topical Effects

When applied to the skin, Peppermint Oil activates TRPM8 cold-sensing receptors, producing a cooling sensation and a counterirritant analgesic effect that is thought to underlie its benefit in tension headache and minor muscle ache.

Pharmacokinetics

Following oral administration of enteric-coated Peppermint Oil, the capsule resists dissolution in gastric acid and releases its contents in the small intestine; menthol and other constituents are absorbed, partly conjugated in the intestinal wall and liver (glucuronidation), and excreted mainly in urine and bile. Topically applied Peppermint Oil is absorbed to a limited extent through intact skin.

• Take Liqumint enteric-coated capsules whole, with a full glass of water, 15-30 minutes before meals; do not crush or chew.
• Avoid concurrent antacids/acid-reducing medicines around the time of dosing with oral Liqumint.
• For topical Liqumint, apply only to clean, intact skin; avoid eyes, lips, nostrils, and broken skin or mucous membranes.
• Do not apply topical or inhaled Liqumint near the face or nose of infants or young children.

• Antacids, H2-receptor antagonists, proton pump inhibitors: Concurrent use can raise gastric pH and cause premature dissolution of the enteric coating of oral Liqumint capsules in the stomach rather than the intestine, reducing efficacy and increasing the likelihood of heartburn. Separate dosing where possible and inform the physician.
• CYP3A4 substrates with a narrow therapeutic index (e.g. cyclosporine): Liqumint constituents may inhibit intestinal/hepatic CYP3A4 metabolism, and case reports describe raised cyclosporine levels with concomitant Liqumint use; concurrent use should be supervised by a physician with monitoring.
• Other gastrointestinal antispasmodics/smooth-muscle relaxants: Additive smooth-muscle relaxant effect is theoretically possible; clinical significance is not well established.

• Common: Heartburn/gastro-oesophageal reflux symptoms (more frequent with non-enteric-coated oral preparations), belching, nausea.
• Less common: Perianal or perirectal burning sensation with oral use; mild abdominal discomfort.
• Topical use: Local skin irritation, burning, or allergic contact dermatitis at the site of application; mucosal irritation if it contacts the eyes, lips, or nostrils.
• Rare: Headache, dizziness, or hypersensitivity reactions.

Pregnancy: Data on medicinal (non-culinary) doses of Liqumint in human pregnancy are insufficient to establish safety. Liqumint should be used in pregnancy only if clearly needed and if the potential benefit justifies the potential risk to the fetus; consult a physician before use.

Lactation: It is not known whether constituents of Liqumint pass into human breast milk in clinically significant amounts. As a precaution, use during breastfeeding should occur only on the advice of a physician, weighing benefit against unknown risk to the infant.

• Do not crush, chew, or break enteric-coated Liqumint capsules; swallow whole to preserve the protective coating.
• Avoid taking oral Liqumint together with antacids or acid-suppressing medicines (see Interactions).
• For topical Liqumint, avoid contact with the eyes, mucous membranes, and broken or irritated skin; discontinue if a rash or irritation develops.
• Do not apply topical or inhaled Liqumint near the face or nose of infants or young children (see Contraindications).
• The evidence base for Liqumint is strongest for enteric-coated oral use in IBS; evidence for topical use in headache and muscle ache is more limited and it should be regarded as a symptomatic, adjunctive measure rather than a cure.
• Seek medical advice if IBS symptoms worsen, if alarm features develop (rectal bleeding, unintended weight loss, anaemia, nocturnal symptoms), or if headache/muscle pain is severe, persistent, or atypical.

Ingestion of Liqumint in amounts substantially greater than the recommended dose, or accidental ingestion of concentrated topical/inhalant Liqumint products, may cause worsened heartburn, nausea, vomiting, abdominal pain, drowsiness, loss of muscle coordination (ataxia), and, rarely, more serious central nervous system effects. There is no specific antidote.

In case of suspected overdose, seek immediate medical attention or contact a poison control center; do not attempt specific home treatment beyond supportive first aid while awaiting medical help.

Store at room temperature (below 30°C), away from light and moisture. Keep the container tightly closed to protect the enteric coating of capsules from humidity. Keep out of reach of children.

• Hepatic impairment: Data are limited; use Liqumint with caution and under medical supervision, as menthol undergoes hepatic metabolism.
• Renal impairment: No well-established dose adjustment is required, but data are limited; use with caution.
• Elderly: No specific dose adjustment is established; use standard adult dosing with attention to concurrent medications and GERD symptoms.
• Infants and young children: Topical/inhaled Liqumint must not be applied near the face or nose (see Contraindications); oral use is not established in this age group.

For IBS, a therapeutic trial of oral enteric-coated Liqumint is typically continued for at least 4 weeks, and response reassessed by a physician; treatment may be continued for up to approximately 3 months if beneficial, with periodic medical review thereafter. For topical use in tension headache or muscle ache, Liqumint is used episodically/as needed rather than on a fixed long-term schedule; persistent or worsening symptoms should prompt medical reassessment rather than indefinite self-treatment.

Herbal medicinal product; Gastrointestinal antispasmodic/spasmolytic; Topical analgesic/counterirritant

Peppermint Oil's principal constituent, menthol, blocks L-type calcium channels in gastrointestinal smooth muscle, producing direct relaxation of gut smooth muscle (antispasmodic effect), and activates TRPM8 receptors on sensory nerve afferents, reducing visceral hypersensitivity in the gut and producing a cooling, counterirritant analgesic effect when applied topically to skin.

Liqumint applied topically or by inhalation must not be used on or near the face or nose of infants and young children because of reported associations between menthol-containing products used this way and laryngospasm/bronchospasm in this age group.

The safety and efficacy of oral enteric-coated Liqumint for IBS have not been firmly established in young children; some studies have evaluated its use in older children/adolescents with IBS under medical supervision, but it is not a first-line, routinely recommended therapy in this age group. Pediatric use of Liqumint, in any form, should occur only on the advice of a pediatrician.